Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

By In The News
February 28, 2019 in The Headlines

Recommended Posts

In The News

Posted February 28, 2019

- Share

Posted February 28, 2019

STOCKHOLM, Feb. 28, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company's novel candidate melflufen, a peptide-conjugated alkylator belonging to the novel class of...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222050
2. Jaydee
  17803
3. deicer
  13356
4. Kip Powick
  12315
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.5k
- Total Posts
  
  565k

Sign In

Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support